RT Journal Article
SR Electronic
T1 Vaccination strategies when vaccines are scarce: On conflicts between reducing the burden and avoiding the evolution of escape mutants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.04.21256623
DO 10.1101/2021.05.04.21256623
A1 Geoffroy, Félix
A1 Traulsen, Arne
A1 Uecker, Hildegard
YR 2021
UL http://medrxiv.org/content/early/2021/05/08/2021.05.04.21256623.abstract
AB When vaccine supply is limited but population immunisation urgent, the allocation of the available doses needs to be carefully considered. One aspect of dose allocation is the time interval between the primer and the booster injections in two-dose vaccines. By stretching this interval, more individuals can be vaccinated with the first dose more quickly. Even if the level of immunity of these ‘half-vaccinated’ individuals is lower than that of those who have received both shots, delaying the second injection can be beneficial in reducing case numbers, provided a single dose is sufficiently effective. On the other hand, there has been concern that intermediate levels of immunity in partially vaccinated individuals may favour the evolution of vaccine escape mutants. In that case, a large fraction of half-vaccinated individuals would pose a risk – but only if they encounter the virus. This raises the question whether there is a conflict between reducing the burden and the risk of vaccine escape evolution or not. We develop a minimal model to assess the population-level effects of the timing of the booster dose. We set up an SIR-type model, in which more and more individuals become vaccinated with a two-dose vaccine over the course of a pandemic. As expected, there is no trade-off when vaccine escape evolves at equal probabilities in unvaccinated and half-vaccinated patients. If vaccine escape evolves more easily in half-vaccinated patients, the presence or absence of a trade-off depends on the reductions in susceptibility and transmissibility elicited by the primer dose.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the German Research Foundation (DFG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:no approval was requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Jupyter notebook for running the model and reproducing the figures is available at: https://github.com/fgeoffroy/Vaccine-escape https://github.com/fgeoffroy/Vaccine-escape